Skip to content

Author

Larry D. Anderson

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Teclistamab Plus Daratumumab Versus Standard Daratumumab-Based Proteasome Inhibitor Combinations for Relapsed/Refractory Multiple Myeloma: An Inverse Probability of Treatment Weighting Analysis.

INTRODUCTION In the phase 3 MajesTEC-3 study (NCT05083169), teclistamab with daratumumab (Tec-Dara) significantly improved progression-free and overall survival (PFS/OS) versus investigator's choice of standard-of-care daratumumab/pomalidomide/dexamethasone (DPd) or daratumumab/bortezomib/dexamethasone (DVd) in patient...

Larry D. Anderson, S. Nair, Mi-Jun Keng et al. · 0 citations
Open access Sep 2026

Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis

Ciltacabtagene autoleucel (cilta‐cel), an anti–B‐cell maturation antigen (BCMA) chimeric antigen receptor T‐cell (CAR‐T) therapy, is approved for relapsed/refractory multiple myeloma (RRMM).

H. Mian, M. Faisal, Tie-Ning Chen et al. · 0 citations
Open access Sep 2026

B-cell maturation antigen -targeted Tirapazamine-loaded liposomes overcome hypoxia-induced drug resistance and metastasis in multiple myeloma.

Multiple myeloma (MM) is a highly fatal disease, particularly in the relapsed-refractory stage, due to drug resistance associated with tumor hypoxia. TPZ, a hypoxia-activated pro-drug, effectively kills hypoxic tumor cells; however, its severe side effects have limited its therapeutic use. This study investigates BCMA-...

M. Maksimos, B. Muz, F. Azab et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.